MedTrace Logo

Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms

NCT06803030 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 189

Last updated 2025-09-08

No results posted yet for this study

Summary

A comparative study on the efficacy of Tamsulosin, Solifenacin and Mirabegron in alleviating ureteral stent-related symptoms: a randomized controlled trial.

Conditions

  • Ureteral Stent-Related Symptom

Interventions

DRUG

Tamsulosin Hydrochloride 0.4 mg

placement of ureteral stents followed by Cap. Tamsulosin 0.4 mg once daily

DRUG

Solifenacin Succinate 5 mg

placement of ureteral stents followed by Tab. Solifenacin 5 mg once daily

DRUG

Mirabegron 25 mg

placement of ureteral stents followed by Tab. Mirabegron 25 mg once daily

Sponsors & Collaborators

  • Nepal Health Research Council

    collaborator OTHER_GOV

  • Bir Hospital

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-30
Primary Completion
2025-12-01
Completion
2026-12-31

Countries

  • Nepal

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06803030 on ClinicalTrials.gov